Last updated on March 2019

A Dose Ranging Study of OPT-302 With Aflibercept for Persistent Diabetic Macular Edema

Brief description of study

A two part, multi-center study consisting of a Phase 1b open label, sequential dose escalation followed by a Phase 2a randomized, double-masked, dose expansion evaluating OPT-302 in combination with aflibercept in participants with persistent central-involved Diabetic Macular Edema.

Clinical Study Identifier: NCT03397264

Find a site near you

Start Over

Opthea Investigational Site

Hagerstown, MD United States
  Connect »